October 3, 2011, Guelph, Ontario, Canada
Ceva today announced the acquisition of CentaurVA Animal Health, a division of Centaur Pharmaceuticals Inc. CentaurVA manufactures and distributes products for small and large animal veterinary practitioners.
This acquisition further expands Ceva’s footprint in North America. Centaur’s broad range of products, including nutraceuticals, joint therapies and infection-control products, along with an experienced staff will provide Ceva with an excellent base for its expansion in the Canadian market. “The move helps in marketing and distributing current Ceva products,” said Craig Wallace, North America Zone Director for Ceva, “and will serve as a strong foundation for future product launches.”
“Canada is an important world economy where we needed to have a direct presence,” said Marc Prikazsky, CEO of Ceva Santé Animale. “Integrating the two companies will lead to an expansion of networks for both teams, and continues Ceva’s growth into new markets.”
About CentaurVA Animal Health: Dr. Charles Povey purchased John E. Slinger Ltd. in 1983. In 1992, he changed the name of the company to Centaur Pharmaceuticals and continued to develop the business into its current success. Dr. Greg Hawkins is president of the Guelph, Ontario company which markets pharmaceuticals, topicals, supplements, diagnostic kits, I.V. sets and nutritional support, and is committed to providing veterinarians across Canada with high quality products and excellence in customer service.
About Ceva: In North America, Ceva’s key companion animal products include the Vectra® line of parasiticides, D.A.P.® and Feliway® pheromone behavior aids and Senilife® neuroprotection for aging pets. Key poultry products include CEVAC® Transmune IBD, Vectormune® FP and Vectormune® HVT. Ceva’s North America Zone headquarters are located in Lenexa, Kansas. Visit www.ceva.us .
>> Click on the link below to download the Press Release :